View Financial HealthProtara Therapeutics 配当と自社株買い配当金 基準チェック /06Protara Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-29.0%バイバック利回り総株主利回り-29.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesProtara Therapeutics, Inc. to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingApr 29Protara Therapeutics, Inc., Annual General Meeting, Jun 12, 2026Apr 21Protara Therapeutics, Inc. Announces Updated Interim Results from its Ongoing Phase 2 Open-Label ADVANCED-2 Trial Assessing Invesical TARA-002Feb 24Protara Therapeutics, Inc. to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of Tara-002 in BCG-Unresponsive NMIBC Patients at the Asco Genitourinary Cancers SymposiumJan 22Protara Therapeutics, Inc. Announces Dosing of First Patient in Phase 3 Registrational Thrive-3 Trial of Iv Choline Chloride in Patients on Long-Term Parenteral SupportJan 08Protara Therapeutics, Inc. Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic MalformationsJan 06Protara Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.000004 million.Dec 05+ 1 more updateProtara Therapeutics: End Of 2025 Proving Eventful Indeed Dec 04Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC PatientsDec 04Protara Therapeutics, Inc. Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNov 20We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business GrowthJul 10Protara Therapeutics, Inc. Announces Appointment of William Conkling as Chief Commercial OfficerJun 04Protara Therapeutics, Inc., Annual General Meeting, Jun 11, 2025Apr 28+ 1 more updateProtara Therapeutics, Inc. Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical OfficerApr 16Protara Therapeutics to Present Interim Analysis from the Phase 2 Advanced-2 Trial of Tara-002 in Patients with NMIBCApr 11Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results Mar 28Protara Therapeutics, Inc. Announces Encore Presentation of Results from Thrive-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportMar 20We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash WiselyMar 07Protara Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.09375 million.Dec 11Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst Dec 10Protara Therapeutics, Inc. has filed a Follow-on Equity Offering.Dec 10Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBCDec 05Protara Therapeutics Announces New Interim Data from Phase 2 Advanced-2 Trial of Tara-002 in Patients with NMIBCDec 03Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn SituationNov 22Protara Therapeutics, Inc. to Present New Interim Data from Phase 2 Advanced-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic OncologyNov 16Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?Aug 08New major risk - Shareholder dilution Apr 29Insufficient new directors Apr 29Protara Therapeutics, Inc., Annual General Meeting, Jun 07, 2024Apr 28New major risk - Revenue and earnings growth Apr 23Price target decreased by 12% to US$27.00 Apr 11Protara Therapeutics, Inc. announced that it expects to receive $44.998327 million in funding from a group of investorsApr 06Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCApr 05+ 1 more updateNew major risk - Financial position Mar 13Protara: A Bombed Out Biotech With A Very Positive Skew Feb 22Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn SituationDec 16Protara Therapeutics, Inc. Announces Presentation of Additional Encouraging Data from Phase 1A Advanced-1 Trial of Tara-002 in Nmibc At the 24Th Annual Meeting of the Society of Urologic OncologyNov 30New minor risk - Share price stability Nov 28New minor risk - Profitability Jul 10Price target decreased by 9.0% to US$31.40 Jul 10Forecast to breakeven in 2025 May 10We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business GrowthApr 22Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial OfficerJan 31High number of new directors Nov 16The Prognosis For Protara Therapeutics Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn SituationSep 12Price target decreased to US$36.00 May 10High number of new directors Apr 27Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?Dec 06Chief Medical Officer Martin Olivo has left the company Nov 29Chief Medical Officer Martin Olivo has left the company Nov 29Chief Medical Officer Martin Olivo has left the company Nov 29Chief Medical Officer Martin Olivo has left the company Nov 29Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 28Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 27Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 26Chief Medical Officer Martin Olivo has left the company Nov 25Chief Medical Officer Martin Olivo has left the company Nov 25Chief Medical Officer Martin Olivo has left the company Nov 25Chief Medical Officer Martin Olivo has left the company Nov 25Chief Medical Officer Martin Olivo has left the company Nov 25Chief Medical Officer Martin Olivo has left the company Nov 25Chief Medical Officer Martin Olivo has left the company Nov 25決済の安定と成長配当データの取得安定した配当: TARAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: TARAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Protara Therapeutics 配当利回り対市場TARA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (TARA)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (TARA) (最長3年)n/a注目すべき配当: TARAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: TARAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: TARAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: TARAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 19:33終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Protara Therapeutics, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Li Wang WatsekCantor Fitzgerald & Co.Andrew FeinH.C. Wainwright & Co.Andres MaldonadoH.C. Wainwright & Co.6 その他のアナリストを表示
Protara Therapeutics, Inc. to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingApr 29
Protara Therapeutics, Inc. Announces Updated Interim Results from its Ongoing Phase 2 Open-Label ADVANCED-2 Trial Assessing Invesical TARA-002Feb 24
Protara Therapeutics, Inc. to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of Tara-002 in BCG-Unresponsive NMIBC Patients at the Asco Genitourinary Cancers SymposiumJan 22
Protara Therapeutics, Inc. Announces Dosing of First Patient in Phase 3 Registrational Thrive-3 Trial of Iv Choline Chloride in Patients on Long-Term Parenteral SupportJan 08
Protara Therapeutics, Inc. Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic MalformationsJan 06
Protara Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.000004 million.Dec 05+ 1 more update
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC PatientsDec 04
Protara Therapeutics, Inc. Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNov 20
Protara Therapeutics, Inc. Announces Appointment of William Conkling as Chief Commercial OfficerJun 04
Protara Therapeutics, Inc. Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical OfficerApr 16
Protara Therapeutics to Present Interim Analysis from the Phase 2 Advanced-2 Trial of Tara-002 in Patients with NMIBCApr 11
Protara Therapeutics, Inc. Announces Encore Presentation of Results from Thrive-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportMar 20
Protara Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.09375 million.Dec 11
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBCDec 05
Protara Therapeutics Announces New Interim Data from Phase 2 Advanced-2 Trial of Tara-002 in Patients with NMIBCDec 03
Protara Therapeutics, Inc. to Present New Interim Data from Phase 2 Advanced-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic OncologyNov 16
Protara Therapeutics, Inc. announced that it expects to receive $44.998327 million in funding from a group of investorsApr 06
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCApr 05+ 1 more update
Protara Therapeutics, Inc. Announces Presentation of Additional Encouraging Data from Phase 1A Advanced-1 Trial of Tara-002 in Nmibc At the 24Th Annual Meeting of the Society of Urologic OncologyNov 30
